KRYS - Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications
- Positive results were obtained from the phase 3 GEM-3 study using VYJUVEK for the treatment of patients with dystrophic Epidermolysis Bullosa.
- STAR-D technology platform is highly efficient in using an engineered non-encoding HSV-1 viral vector to deliver a large gene or multiple genes to restore a functioning protein.
- KB-105 is a gene therapy targeting a skin disease known as TGM1-deficient autosomal recessive congenital ichthyosis; Phase 2 cohort to resume in 2022.
- Krystal Biotech wholly owned subsidiary, Jeune Aesthetics, Inc. is expected to release data, from a phase 1 proof of concept study using intradermal delivery of KB301 to restore gene COL3A1, in early 2022.
For further details see:
Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications